← All indications
Conjunctivitis
INFLAMMATION of the CONJUNCTIVA.
Subtype terms (4)
More specific conditions that are subtypes of Conjunctivitis in the MeSH hierarchy.
- Conjunctivitis, Allergic
85 drugs (46 approved, 39 experimental)
- Conjunctivitis, Bacterial
29 drugs (23 approved, 6 experimental)
- Conjunctivitis, Viral
8 drugs (7 approved, 1 experimental)
- Keratoconjunctivitis
11 drugs (7 approved, 4 experimental)
Drugs by status
Approved for this indication (7)
Phase 4 trials (21)
Phase 3 trials (32)
- tavilermide
- brimonidine
- azelastine
- ebi-005
- parietaria judaica pollen extract
- epoetin
- besifloxacin
- loratadine
- mometasone
- epinastine
- tacrolimus
- plasminogen
- autologous serum
- iodine
- succinylcholine
- sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract
- acetaminophen
- short ragweed pollen allergen
- pentoxifylline
- trifolium pratense
- al0704rp
- cat epidermis allergen
- azithromycin
- albuterol
- desloratadine
- alk alutard 5-grasses
- regn5713
- regn5714
- regn5715
- Pollinex Quattro Grass
- +2 more
Phase 2 trials (38)
- vitamin d3
- auriclosene
- avanz salsola
- carrageenan
- coversin
- cyt005-allqbg10
- dialyzable leukocyte extracts
- dupilumab
- leuprolide
- aldesleukin
- baricitinib
- mg56
- serum
- pilocarpine
- ranpirnase
- rbet v1-fv
- mycophenolate
- toleromune hdm
- cellulose
- allogeneic adipose derived mesenchymal stem cell
- cupressus arizonica
- escherichia coli nissle 1917
- methotrexate
- cyt003-qbg10
- depigold olea europea
- depigold judaica
- fatty acid
- oak tree allergen
- prednisolone
- sodium chloride
- +8 more
Phase 1 trials (13)
Organizations
Organization Involved with Phase 4 Indications (37)
- Bausch Health Companies
- Bausch & Lomb
- Alcon
- Allergan
- GlaxoSmithKline
- Laboratoires Thea
- ORA, Inc.
- Samil Pharmaceutical Co., Ltd.
- Starx Research Center, LLC
- Lifelong Vision Foundation
- Hom, Milton M., OD, FAAO
- Aston University
- Harvard University
- Kyoto Prefectural University of Medicine
- Mahidol University
- Meiji University of Oriental Medicine
- Ophthalmic Consultants of Boston
- Siriraj Hospital
- Southern California College of Optometry
- Tufts University
- University of Iowa
- University of Rochester
- University of the Philippines
- Virginia Eye Consultants
- Rush University
- Toyos Clinic
- University of Montreal
- Eye Surgeons of Indiana
- Brar-Parekh Eye Associates
- Minnesota Eye Consultants
- +7 more
Organization Involved with Phase 3 Indications (50)
- Aciex Therapeutics, Inc.
- Adapt Produtos Oftalmológicos Ltda.
- Shire
- ISTA Pharmaceuticals
- Astellas
- Stallergenes
- Akorn, Inc.
- Aldeyra Therapeutics, Inc.
- Allergopharma GmbH & Co. KG
- Artu Biologicals
- Santen Inc.
- Circassia Limited
- Faes Farma, S.A.
- HAL Allergy
- InSite Vision
- Kurobe LLC
- Kala Pharmaceuticals, Inc.
- Laboratorios Sophia S.A de C.V.
- Leti Pharma GmbH
- Ocular Therapeutix, Inc.
- Vistakon Pharmaceuticals
- Fundação Altino Ventura
- Laser Microsurgery Centre, Poland
- Medical University of Warsaw
- Memorial University of Newfoundland
- Wroclaw Medical University
- University of Cincinnati
- inVentiv
- University of Campinas
- Azidus
- +20 more
Organization Involved with Phase 2 Indications (72)
- Novelion Therapeutics
- Senju Pharmaceuticals
- Adenovir Pharma AB
- ASIT Biotech S.A.
- Anergis
- C.T. Development America, Inc.
- Eye Therapies, LLC
- Harrison Clinical Research
- Inmunotek S.L.
- Mati Therapeutics Inc.
- NicOx
- Noveome Biotherapeutics
- Cytos Biotechnology AG
- Roxall Medizin
- National Polytechnic Institute, Mexico
- Hospital Universitario Getafe
- Koffler Vision Group
- Medical University of Lodz
- St. Erik Eye Hospital
- Universidad Autonoma de Madrid
- Universidad Complutense de Madrid
- Universidad de Murcia
- University of Melbourne
- University of Valencia
- Tel Aviv University
- University of Cape Town
- University of Cologne
- Uppsala University
- Andover Eye Associates
- Badalona Hospital Germans Trias i Pujol
- +42 more
Organization Involved with Phase 1 Indications (13)
Organization Involved with Other Experimental Indications (12)